SG146627A1 - Imidazole derivatives - Google Patents
Imidazole derivativesInfo
- Publication number
- SG146627A1 SG146627A1 SG200806715-9A SG2008067159A SG146627A1 SG 146627 A1 SG146627 A1 SG 146627A1 SG 2008067159 A SG2008067159 A SG 2008067159A SG 146627 A1 SG146627 A1 SG 146627A1
- Authority
- SG
- Singapore
- Prior art keywords
- imidazole derivatives
- treating
- disorders
- medicaments
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03019604 | 2003-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG146627A1 true SG146627A1 (en) | 2008-10-30 |
Family
ID=34224067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200806715-9A SG146627A1 (en) | 2003-09-04 | 2004-08-27 | Imidazole derivatives |
Country Status (21)
Country | Link |
---|---|
US (2) | US7452909B2 (es) |
EP (1) | EP1831193B1 (es) |
JP (1) | JP4490423B2 (es) |
KR (2) | KR100893957B1 (es) |
CN (1) | CN1875016B (es) |
AR (1) | AR045548A1 (es) |
AT (1) | ATE427945T1 (es) |
AU (1) | AU2004270352B2 (es) |
BR (1) | BRPI0414148A (es) |
CA (1) | CA2537826C (es) |
CO (1) | CO5650235A2 (es) |
DE (1) | DE602004020525D1 (es) |
ES (1) | ES2321408T3 (es) |
IL (1) | IL173911A (es) |
MX (1) | MXPA06002453A (es) |
NO (1) | NO20061045L (es) |
RU (1) | RU2345074C2 (es) |
SG (1) | SG146627A1 (es) |
TW (1) | TWI290138B (es) |
WO (1) | WO2005023795A1 (es) |
ZA (1) | ZA200601865B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8204149B2 (en) | 2003-12-17 | 2012-06-19 | Qualcomm Incorporated | Spatial spreading in a multi-antenna communication system |
US8169889B2 (en) | 2004-02-18 | 2012-05-01 | Qualcomm Incorporated | Transmit diversity and spatial spreading for an OFDM-based multi-antenna communication system |
US8923785B2 (en) | 2004-05-07 | 2014-12-30 | Qualcomm Incorporated | Continuous beamforming for a MIMO-OFDM system |
DK1756086T3 (da) * | 2004-06-01 | 2008-08-04 | Hoffmann La Roche | Pyridin-4-yl-ethynyl-imidazoler og pyrazoler som mglu5-receptorantagonister |
DE602005007350D1 (de) * | 2004-06-01 | 2008-07-17 | Hoffmann La Roche | Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors |
US7978649B2 (en) | 2004-07-15 | 2011-07-12 | Qualcomm, Incorporated | Unified MIMO transmission and reception |
US8543070B2 (en) | 2006-04-24 | 2013-09-24 | Qualcomm Incorporated | Reduced complexity beam-steered MIMO OFDM system |
ES2577391T3 (es) | 2006-12-21 | 2016-07-14 | F. Hoffmann-La Roche Ag | Polimorfos de un antagonista del receptor mglur5 |
WO2009097414A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Use of imidazolylalkyl-pyridines for the treatment of addictive disorders |
US8334287B2 (en) * | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2084702T3 (es) * | 1989-06-30 | 1996-05-16 | Du Pont | Imidazoles sustituidos utiles como inhibidores de la angiotensina ii. |
AU780009B2 (en) | 1999-08-31 | 2005-02-24 | Merck Sharp & Dohme Corp. | Heterocyclic compounds and methods of use thereof |
US20040259917A1 (en) * | 2001-12-19 | 2004-12-23 | Cosford Nicholas D.P. | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
UA80888C2 (en) | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
ATE495168T1 (de) * | 2003-06-12 | 2011-01-15 | Hoffmann La Roche | Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten |
US7091222B2 (en) * | 2003-07-03 | 2006-08-15 | Hoffmann-La Roche Inc. | Imidazole derivatives |
-
2004
- 2004-08-26 US US10/926,670 patent/US7452909B2/en not_active Expired - Fee Related
- 2004-08-27 MX MXPA06002453A patent/MXPA06002453A/es active IP Right Grant
- 2004-08-27 KR KR1020077026004A patent/KR100893957B1/ko not_active IP Right Cessation
- 2004-08-27 SG SG200806715-9A patent/SG146627A1/en unknown
- 2004-08-27 JP JP2006525079A patent/JP4490423B2/ja not_active Expired - Fee Related
- 2004-08-27 KR KR1020067004489A patent/KR100811898B1/ko not_active IP Right Cessation
- 2004-08-27 WO PCT/EP2004/009558 patent/WO2005023795A1/en active Application Filing
- 2004-08-27 EP EP04764532A patent/EP1831193B1/en not_active Not-in-force
- 2004-08-27 CA CA2537826A patent/CA2537826C/en not_active Expired - Fee Related
- 2004-08-27 ES ES04764532T patent/ES2321408T3/es active Active
- 2004-08-27 RU RU2006110537/04A patent/RU2345074C2/ru not_active IP Right Cessation
- 2004-08-27 DE DE602004020525T patent/DE602004020525D1/de active Active
- 2004-08-27 CN CN2004800321399A patent/CN1875016B/zh not_active Expired - Fee Related
- 2004-08-27 BR BRPI0414148-2A patent/BRPI0414148A/pt not_active IP Right Cessation
- 2004-08-27 AU AU2004270352A patent/AU2004270352B2/en not_active Ceased
- 2004-08-27 AT AT04764532T patent/ATE427945T1/de active
- 2004-09-01 TW TW093126399A patent/TWI290138B/zh not_active IP Right Cessation
- 2004-09-01 AR ARP040103128A patent/AR045548A1/es unknown
-
2006
- 2006-02-23 IL IL173911A patent/IL173911A/en not_active IP Right Cessation
- 2006-02-27 CO CO06019310A patent/CO5650235A2/es not_active Application Discontinuation
- 2006-03-03 NO NO20061045A patent/NO20061045L/no not_active Application Discontinuation
- 2006-03-03 ZA ZA200601865A patent/ZA200601865B/en unknown
-
2008
- 2008-09-17 US US12/211,849 patent/US7964620B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200716120A (en) | Pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
TW200716121A (en) | Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
TNSN05194A1 (en) | Substituted n-arylheterocycles, method for production and use thereof as medicaments | |
WO2006024486A3 (en) | Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents | |
MY140693A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
MY139302A (en) | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
TW200740789A (en) | Pyridine and pyrimidine derivatives as mGluR2 antagonists | |
TW200621262A (en) | New dihydropteridione derivatives, process for their manufacture and their use as medicament | |
TW200621777A (en) | New dihydropteridione derivatives, process for their manufacture and their use as medicament | |
MY133392A (en) | Novel substituted pyrazole derivatives | |
MY139303A (en) | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
RS20050195A (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
GB0313612D0 (en) | Organic compounds | |
TW200714598A (en) | Urea derivatives, methods for their manufacture, and uses therefor | |
YU99702A (sh) | Derivati sulfonil-pirolidina | |
WO2008080844A9 (en) | Azaspiro derivatives | |
MX2007010414A (es) | Derivados de piridin-2-carboxamida como antagonistas de mglur5. | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
ES2193875A1 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. | |
MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
MX2009010505A (es) | Derivados de piridina y pirimidina como antagonistas de mglur2. | |
MX2009006010A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2. | |
PL1745010T3 (pl) | Podstawione pochodne cykloheksylo-1,4-diaminy |